Oceanpine Capital leads $73m funding in US biopharma firm Immune-Onc
Oceanpine Capital leads $73m funding in US biopharma firm Immune-Onc April 1, 2021 Immune-Onc Therapeutics, a California-based cancer immunotherapy firm co-founded by Chinese pharma specialist Charlene Liao, has raised $73 million in Series B1 and B2 rounds of financing, it announced earlier this week. The latest funding brings the total capital raised by the company to $110 million, it said in a statement. Beijing-headquartered Oceanpine Capital was the lead investor in the two rounds, which were joined by return backers Northern Light Venture Capital and Vivo Capital. Following the fin...
Source: dealstreetasia.com